Carsten Tschöpe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/116713/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Novel Paradigm for Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2013, 62, 263-271.	2.8	2,555
2	How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal, 2007, 28, 2539-2550.	2.2	2,302
3	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. New England Journal of Medicine, 2015, 373, 929-938.	27.0	1,827
4	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	2.2	944
5	Utility of Doppler Echocardiography and Tissue Doppler Imaging in the Estimation of Diastolic Function in Heart Failure With Normal Ejection Fraction. Circulation, 2007, 116, 637-647.	1.6	917
6	Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2013, 309, 781.	7.4	604
7	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nature Reviews Cardiology, 2021, 18, 169-193.	13.7	589
8	Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction. Circulation: Heart Failure, 2011, 4, 44-52.	3.9	493
9	Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). European Heart Journal, 2013, 34, 512-519.	2.2	472
10	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
11	Crosstalk between fibroblasts and inflammatory cells. Cardiovascular Research, 2014, 102, 258-269.	3.8	419
12	Role of Left Ventricular Stiffness in Heart Failure With Normal Ejection Fraction. Circulation, 2008, 117, 2051-2060.	1.6	403
13	Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 312-324.	4.1	390
14	Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007405.	3.9	353
15	Inflammation – Cause or Consequence of Heart Failure or Both?. Current Heart Failure Reports, 2017, 14, 251-265.	3.3	324
16	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	2.2	304
17	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 119-129.	7.1	281
18	Diastolic Tissue Doppler Indexes Correlate With the Degree of Collagen Expression and Cross-Linking in Heart Failure and Normal Ejection Fraction. Journal of the American College of Cardiology, 2011, 57, 977-985.	2.8	273

#	Article	IF	CITATIONS
19	The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. European Heart Journal, 2005, 26, 2277-2284.	2.2	258
20	Angiotensin II Type 2 Receptor Stimulation. Circulation, 2008, 118, 2523-2532.	1.6	250
21	Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy: The Role of Angiotensin Type 1 Receptor Antagonism. Diabetes, 2007, 56, 641-646.	0.6	244
22	Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model. Circulation: Heart Failure, 2013, 6, 1239-1249.	3.9	241
23	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	7.1	239
24	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	2.8	224
25	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	7.1	224
26	Complication Rate of Right Ventricular Endomyocardial Biopsy via the Femoral Approach. Circulation, 2008, 118, 1722-1728.	1.6	223
27	Potential Usefulness and Clinical RelevanceÂof Adding Left Atrial Strain to LeftÂAtrialÂVolume Index in the Detection of Left Ventricular Diastolic Dysfunction. JACC: Cardiovascular Imaging, 2018, 11, 1405-1415.	5.3	215
28	Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy. Circulation, 2009, 119, 1241-1252.	1.6	200
29	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412.	7.1	193
30	Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nature Communications, 2016, 7, 13710.	12.8	190
31	Protective Role of Angiopoietin-1 in Endotoxic Shock. Circulation, 2005, 111, 97-105.	1.6	189
32	SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovascular Research, 2020, 116, 2207-2215.	3.8	189
33	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
34	Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Research in Cardiology, 2007, 102, 500-507.	5.9	180
35	Management of Myocarditis-Related Cardiomyopathy in Adults. Circulation Research, 2019, 124, 1568-1583.	4.5	179
36	Empagliflozin improves endothelial and cardiomyocyte functionÂin human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovascular Research, 2021, 117, 495-507.	3.8	167

Carsten TschĶpe

#	Article	IF	CITATIONS
37	Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Research in Cardiology, 2008, 103, 319-327.	5.9	165
38	Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice. Cancer Research, 2009, 69, 695-699.	0.9	165
39	Empagliflozin directly improves diastolic function in human heart failure. European Journal of Heart Failure, 2018, 20, 1690-1700.	7.1	165
40	Impact of Dopamine Infusion on Renal Function in Hospitalized Heart Failure Patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. Journal of Cardiac Failure, 2010, 16, 922-930.	1.7	153
41	Galectinâ€3 in patients with heart failure with preserved ejection fraction: results from the Aldoâ€ <scp>DHF</scp> trial. European Journal of Heart Failure, 2015, 17, 214-223.	7.1	146
42	Tollâ€like receptorâ€4 deficiency attenuates doxorubicinâ€induced cardiomyopathy in mice. European Journal of Heart Failure, 2008, 10, 233-243.	7.1	136
43	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. European Heart Journal, 2016, 37, 2823-2829.	2.2	136
44	Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Research in Cardiology, 2014, 109, 428.	5.9	128
45	Normal range and usefulness of right ventricular systolic strain to detect subtle right ventricular systolic abnormalities in patients with heart failure: a multicentre study. European Heart Journal Cardiovascular Imaging, 2017, 18, 212-223.	1.2	126
46	Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts. Journal of Cardiovascular Translational Research, 2019, 12, 116-123.	2.4	125
47	Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy. Diabetes, 2007, 56, 1834-1841.	0.6	121
48	Role of Gender in Heart Failure with Normal Left Ventricular Ejection Fraction. Progress in Cardiovascular Diseases, 2007, 49, 241-251.	3.1	121
49	Quantification of Circulating Endothelial Progenitor Cells Using the Modified ISHAGE Protocol. PLoS ONE, 2010, 5, e13790.	2.5	120
50	The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy, 2009, 11, 427-434.	0.7	116
51	Transgenic activation of the kallikreinâ€kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy. FASEB Journal, 2005, 19, 2057-2059.	0.5	114
52	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. Cardiovascular Research, 2013, 99, 111-120.	3.8	113
53	Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB Journal, 2000, 14, 1858-1860.	0.5	112
54	Toll-Like Receptor-4 Modulates Survival by Induction of Left Ventricular Remodeling after Myocardial Infarction in Mice. Journal of Immunology, 2008, 180, 6954-6961.	0.8	112

#	Article	IF	CITATIONS
55	Doppler Echocardiography Yields Dubious Estimates of Left Ventricular Diastolic Pressures. Circulation, 2009, 120, 810-820.	1.6	111
56	Transcatheter Implantation of the MONARC Coronary Sinus Device for Mitral Regurgitation. JACC: Cardiovascular Interventions, 2011, 4, 115-122.	2.9	108
57	Multiple Interactions Between the Renin-Angiotensin and the Kallikrein-Kinin Systems: Role of ACE Inhibition and AT1 Receptor Blockade. Journal of Cardiovascular Pharmacology, 2002, 39, 478-487.	1.9	105
58	Truncation of Titin's Elastic PEVK Region Leads to Cardiomyopathy With Diastolic Dysfunction. Circulation Research, 2009, 105, 557-564.	4.5	105
59	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. European Journal of Heart Failure, 2021, 23, 854-871.	7.1	105
60	Human Apolipoprotein A-I Gene Transfer Reduces the Development of Experimental Diabetic Cardiomyopathy. Circulation, 2008, 117, 1563-1573.	1.6	103
61	Cardiac Deletion of the Coxsackievirus-Adenovirus Receptor Abolishes Coxsackievirus B3 Infection and Prevents Myocarditis In Vivo. Journal of the American College of Cardiology, 2009, 53, 1219-1226.	2.8	103
62	Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovascular Research, 2002, 56, 235-247.	3.8	102
63	Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis During the Development of Experimental Diabetic Cardiomyopathy. Diabetes, 2009, 58, 1373-1381.	0.6	102
64	Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovascular Research, 2020, 116, 806-816.	3.8	102
65	Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. European Heart Journal, 2009, 30, 3027-3036.	2.2	100
66	Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB Journal, 2004, 18, 828-835.	0.5	97
67	Management of heart failure patients with <scp>COVID</scp> â€19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 941-956.	7.1	95
68	Renin Inhibition Improves Cardiac Function and Remodeling After Myocardial Infarction Independent of Blood Pressure. Hypertension, 2008, 52, 1068-1075.	2.7	91
69	Ubiquitin-Like Protein ISG15 (Interferon-Stimulated Gene of 15 kDa) in Host Defense Against Heart Failure in a Mouse Model of Virus-Induced Cardiomyopathy. Circulation, 2014, 130, 1589-1600.	1.6	91
70	Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. European Heart Journal, 2017, 38, 2936-2943.	2.2	91
71	A Common <i>MLP</i> (Muscle LIM Protein) Variant Is Associated With Cardiomyopathy. Circulation Research, 2010, 106, 695-704.	4.5	90
72	Differential Expression of Matrix Metalloproteases in Human Fibroblasts with Different Origins. Biochemistry Research International, 2012, 2012, 1-10.	3.3	90

#	Article	IF	CITATIONS
73	Transgenic overexpression of the sarcoplasmic reticulum Ca 2+ ATPase improves reticular Ca 2+ handling in normal and diabetic rat hearts. FASEB Journal, 2002, 16, 1657-1659.	0.5	88
74	Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial. American Heart Journal, 2021, 234, 1-11.	2.7	88
75	Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. European Heart Journal, 2007, 28, 821-828.	2.2	86
76	The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy. Cancer Research, 2007, 67, 10428-10435.	0.9	85
77	Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. European Journal of Heart Failure, 2006, 8, 115-121.	7.1	83
78	Reduced Degradation of the Chemokine MCP-3 by Matrix Metalloproteinase-2 Exacerbates Myocardial Inflammation in Experimental Viral Cardiomyopathy. Circulation, 2011, 124, 2082-2093.	1.6	81
79	Human Parvovirus B19 NS1 Protein Modulates Inflammatory Signaling by Activation of STAT3/PIAS3 in Human Endothelial Cells. Journal of Virology, 2008, 82, 7942-7952.	3.4	80
80	Global strain rate imaging for the estimation of diastolic function in HFNEF compared with pressure-volume loop analysis. European Journal of Echocardiography, 2010, 11, 743-751.	2.3	80
81	Blocking the IL-1β signalling pathway prevents chronic viral myocarditis and cardiac remodeling. Basic Research in Cardiology, 2019, 114, 11.	5.9	79
82	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. European Heart Journal, 2019, 40, 2142-2151.	2.2	79
83	New Insights in (Inter)Cellular Mechanisms by Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2014, 11, 436-444.	3.3	78
84	Circulating Rather Than Cardiac Angiotensin-(1-7) Stimulates Cardioprotection After Myocardial Infarction. Circulation: Heart Failure, 2010, 3, 286-293.	3.9	77
85	Vascular-Protective Effects of High-Density Lipoprotein Include the Downregulation of the Angiotensin II Type 1 Receptor. Hypertension, 2009, 53, 682-687.	2.7	76
86	Update on Myocarditis and Inflammatory Cardiomyopathy: Reemergence of Endomyocardial Biopsy. Revista Espanola De Cardiologia (English Ed), 2016, 69, 178-187.	0.6	76
87	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
88	Left Ventricular Dysfunction Induced by Nonsevere Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 181-189.	5.6	74
89	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology, 2020, 109, 1079-1098.	3.3	74
90	Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. Journal of Molecular Medicine, 2008, 86, 987-997.	3.9	73

#	Article	IF	CITATIONS
91	Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart, 2017, 4, e000630.	2.3	72
92	Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis Association with reduced myocardial interleukin-1l² and MMP-8 expression and a modulated immune response. European Journal of Heart Failure, 2005, 7, 444-452.	7.1	71
93	Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis, 2010, 210, 438-444.	0.8	71
94	TRIF Is a Critical Survival Factor in Viral Cardiomyopathy. Journal of Immunology, 2011, 186, 2561-2570.	0.8	71
95	Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clinical Research in Cardiology, 2016, 105, 1011-1020.	3.3	71
96	Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond. European Journal of Heart Failure, 2019, 21, 14-22.	7.1	71
97	Role of Heart Rate Reduction in the Prevention of Experimental Heart Failure. Hypertension, 2012, 59, 949-957.	2.7	69
98	Impact of Atrial Fibrillation on the Accuracy of Oscillometric Blood Pressure Monitoring. Hypertension, 2013, 62, 579-584.	2.7	68
99	Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus Receptor. Circulation, 2009, 120, 2358-2366.	1.6	67
100	Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Research in Cardiology, 2012, 107, 308.	5.9	66
101	Heart failure with preserved ejection fraction: current management and future strategies. Clinical Research in Cardiology, 2018, 107, 1-19.	3.3	64
102	Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Research in Cardiology, 2009, 104, 499-509.	5.9	63
103	Interferon Beta Modulates Endothelial Damage in Patients with Cardiac Persistence of Human Parvovirus B19 Infection. Journal of Infectious Diseases, 2010, 201, 936-945.	4.0	63
104	Pathogenic Role of the Damage-Associated Molecular Patterns S100A8 and S100A9 in Coxsackievirus B3–Induced Myocarditis. Circulation: Heart Failure, 2017, 10, .	3.9	63
105	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e010881.	3.7	63
106	Elevated Sera sST2 Is Associated With Heart Failure in Men â‰ 9 0ÂYears Old With Myocarditis. Journal of the American Heart Association, 2019, 8, e008968.	3.7	62
107	Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis. Heart, 2011, 97, 709-714.	2.9	61
108	Protease-Activated Receptor-2 Regulates the Innate Immune Response to Viral Infection in a Coxsackievirus B3–Induced Myocarditis. Journal of the American College of Cardiology, 2013, 62, 1737-1745.	2.8	61

#	Article	IF	CITATIONS
109	Accelerated Mitochondrial Adenosine Diphosphate/Adenosine Triphosphate Transport Improves Hypertension-Induced Heart Disease. Circulation, 2007, 115, 333-344.	1.6	60
110	NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis. Circulation: Heart Failure, 2017, 10, .	3.9	60
111	High-Density Lipoproteins Reduce Endothelial-to-Mesenchymal Transition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1774-1777.	2.4	58
112	Upregulation of bradykinin B1-receptor expression after myocardial infarction. British Journal of Pharmacology, 2000, 129, 1537-1538.	5.4	57
113	Mesenchymal Stromal Cells Modulate Monocytes Trafficking in Coxsackievirus B3-Induced Myocarditis. Stem Cells Translational Medicine, 2017, 6, 1249-1261.	3.3	56
114	The angiotensin-(1–7) receptor agonist AVE0991 is cardioprotective in diabetic rats. European Journal of Pharmacology, 2008, 590, 276-280.	3.5	55
115	Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis. Basic Research in Cardiology, 2014, 109, 449.	5.9	55
116	LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects. Atherosclerosis, 2014, 232, 1-9.	0.8	55
117	New Echocardiographic Findings Correlate with Intramyocardial Inflammation in Endomyocardial Biopsies of Patients with Acute Myocarditis and Inflammatory Cardiomyopathy. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	54
118	Activation of mitochondrial energy metabolism protects against cardiac failure. Aging, 2010, 2, 843-853.	3.1	53
119	Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction. International Journal of Cardiology, 2013, 168, 4652-4657.	1.7	51
120	Mesenchymal stromal cells inhibit NLRP3 inflammasome activation in a model of Coxsackievirus B3-induced inflammatory cardiomyopathy. Scientific Reports, 2018, 8, 2820.	3.3	49
121	Mode-of-action of the PROPELLA concept in fulminant myocarditis. European Heart Journal, 2019, 40, 2164-2169.	2.2	49
122	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	2.2	49
123	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22.	1.9	49
124	Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. European Journal of Pharmacology, 2007, 569, 204-211.	3.5	48
125	Immunomodulation and matrix metalloproteinases in viral myocarditis. Journal of Molecular and Cellular Cardiology, 2010, 48, 468-473.	1.9	48
126	Interleukin-23 Deficiency Leads to Impaired Wound Healing and Adverse Prognosis After Myocardial Infarction. Circulation: Heart Failure, 2014, 7, 161-171.	3.9	48

#	Article	IF	CITATIONS
127	Mesenchymal Stromal Cells but Not Cardiac Fibroblasts Exert Beneficial Systemic Immunomodulatory Effects in Experimental Myocarditis. PLoS ONE, 2012, 7, e41047.	2.5	48
128	Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. Journal of Hypertension, 2000, 18, 223-228.	0.5	47
129	The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovascular Research, 2004, 61, 559-569.	3.8	45
130	Human Cardiac-Derived Adherent Proliferating Cells Reduce Murine Acute Coxsackievirus B3-Induced Myocarditis. PLoS ONE, 2011, 6, e28513.	2.5	44
131	Viral myocarditis and coagulopathy: Increased tissue factor expression and plasma thrombogenicity. Journal of Molecular and Cellular Cardiology, 2008, 45, 118-126.	1.9	43
132	High-Density Lipoprotein at the Interface of Type 2 Diabetes Mellitus And Cardiovascular Disorders. Current Pharmaceutical Design, 2010, 16, 1504-1516.	1.9	43
133	Myeloid differentiation factor-88 contributes to TLR9-mediated modulation of acute coxsackievirus B3-induced myocarditis in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H2024-H2031.	3.2	43
134	Analysis of endomyocardial biopsies in suspected myocarditis—Diagnostic value of left versus right ventricular biopsy. International Journal of Cardiology, 2014, 177, 76-78.	1.7	42
135	Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF. International Journal of Cardiology, 2016, 203, 1061-1066.	1.7	42
136	Right ventricular strain in heart failure: Clinical perspective. Archives of Cardiovascular Diseases, 2017, 110, 562-571.	1.6	42
137	Immunomodulation by adoptive regulatory Tâ€cell transfer improves Coxsackievirus B3â€induced myocarditis. FASEB Journal, 2018, 32, 6066-6078.	0.5	42
138	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	1.7	42
139	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	2.8	42
140	The role of the renal kallikrein–kinin system in diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2007, 16, 22-26.	2.0	41
141	Viral myocarditis. Current Opinion in Cardiology, 2018, 33, 325-333.	1.8	41
142	Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. International Immunopharmacology, 2002, 2, 1823-1832.	3.8	40
143	Clinical Relevance of Left Atrial Strain to Predict Recurrence of Atrial Fibrillation after Catheter Ablation: A Metaâ€Analysis. Echocardiography, 2016, 33, 724-733.	0.9	40
144	The MOGE(S) classification for cardiomyopathies: current status and future outlook. Heart Failure Reviews, 2017, 22, 743-752.	3.9	40

#	Article	IF	CITATIONS
145	<scp>SARSâ€CoVâ€2</scp> â€related myocarditisâ€like syndromes <scp>S</scp> hakespeare's question: what a name?. European Journal of Heart Failure, 2020, 22, 922-925.	s in _{. 7.1}	40
146	Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction. European Heart Journal, 2019, 40, 3318-3332.	2.2	39
147	Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK ₁ and NK ₂ receptors in the rat. British Journal of Pharmacology, 1992, 107, 750-755.	5.4	38
148	Multimodality imaging approach in the diagnosis of chronic myocarditis with preserved left ventricular ejection fraction (MCpEF): The role of 2D speckle-tracking echocardiography. International Journal of Cardiology, 2017, 243, 374-378.	1.7	38
149	Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence. European Journal of Heart Failure, 2019, 21, 1468-1469.	7.1	38
150	Increased kallikrein expression protects against cardiac ischemia. FASEB Journal, 2000, 14, 1861-1863.	0.5	37
151	Cardioprotection by placenta-derived stromal cells in a murine myocardial infarction model. Journal of Surgical Research, 2013, 185, 70-83.	1.6	37
152	Cardiac Fibroblasts Aggravate Viral Myocarditis: Cell Specific Coxsackievirus B3 Replication. Mediators of Inflammation, 2014, 2014, 1-14.	3.0	37
153	Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). Clinical Research in Cardiology, 2018, 107, 991-1002.	3.3	37
154	Myocarditis in athletes: A clinical perspective. European Journal of Preventive Cardiology, 2021, 28, 1050-1057.	1.8	37
155	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	7.1	37
156	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac Failure Review, 2020, 6, e19.	3.0	37
157	Single-beat estimation of the left ventricular end-diastolic pressure-volume relationship in patients with heart failure. Heart, 2010, 96, 213-219.	2.9	36
158	Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation. Journal of Molecular Medicine, 2011, 89, 151-160.	3.9	36
159	Telbivudine in chronic lymphocytic myocarditis and human parvovirus <scp>B19</scp> transcriptional activity. ESC Heart Failure, 2018, 5, 818-829.	3.1	36
160	Localization of the substance P-induced cardiovascular responses in the rat hypothalamus. Brain Research, 1991, 558, 123-126.	2.2	35
161	Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. Immunopharmacology, 1999, 44, 35-42.	2.0	35
162	Elevated NT-ProBNP Levels in Patients With Increased Left Ventricular Filling Pressure During Exercise Despite Preserved Systolic Function. Journal of Cardiac Failure, 2005, 11, S28-S33.	1.7	34

#	Article	IF	CITATIONS
163	Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction — Results of the Aldo-DHF trial. International Journal of Cardiology, 2013, 169, 408-417.	1.7	34
164	Diastolic pressure–volume quotient (DPVQ) as a novel echocardiographic index for estimation of LV stiffness in HFpEF. Clinical Research in Cardiology, 2015, 104, 955-963.	3.3	34
165	Impaired Endothelial Regeneration Through Human Parvovirus B19–Infected Circulating Angiogenic Cells in Patients With Cardiomyopathy. Journal of Infectious Diseases, 2015, 212, 1070-1081.	4.0	34
166	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 279-287.	2.4	34
167	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. European Heart Journal, 2021, 42, 1940-1958.	2.2	34
168	Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. Journal of Cardiovascular Pharmacology, 2018, 71, 129-136.	1.9	33
169	Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clinical Research in Cardiology, 2021, 110, 555-568.	3.3	33
170	COVID-19 vs. Classical Myocarditis Associated Myocardial Injury Evaluated by Cardiac Magnetic Resonance and Endomyocardial Biopsy. Frontiers in Cardiovascular Medicine, 2021, 8, 737257.	2.4	33
171	Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. European Journal of Pharmacology, 2007, 554, 60-68.	3.5	32
172	Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. European Journal of Heart Failure, 2014, 16, 1066-1072.	7.1	32
173	Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series. European Heart Journal - Case Reports, 2019, 3, .	0.6	32
174	Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study. ESC Heart Failure, 2019, 6, 146-153.	3.1	32
175	Left ventricular enlargement in coxsackievirus-B3 induced chronic myocarditis — ongoing inflammation and an imbalance of the matrix degrading system. European Journal of Pharmacology, 2010, 630, 145-151.	3.5	31
176	Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clinical Research in Cardiology, 2014, 103, 665-673.	3.3	31
177	First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in Germany. Journal of Heart and Lung Transplantation, 2021, 40, 850-855.	0.6	31
178	Protection against oxidative stress in diabetic rats: Role of angiotensin AT1 receptor and beta 1-adrenoceptor antagonism. European Journal of Pharmacology, 2005, 520, 179-187.	3.5	30
179	Diastolic heart failure: What we still don't know. Herz, 2012, 37, 875-879.	1.1	30
180	The utility of speckle tracking imaging in the diagnostic of acute myocarditis, as proven by endomyocardial biopsy. International Journal of Cardiology, 2013, 168, 3023-3024.	1.7	30

#	Article	IF	CITATIONS
181	Heterogeneous responses of systolic and diastolic left ventricular function to exercise in patients with heart failure and preserved ejection fraction. ESC Heart Failure, 2015, 2, 121-132.	3.1	30
182	Evaluation of 2 Existing Diagnostic Scores for Heart Failure With Preserved Ejection Fraction Against a Comprehensively Phenotyped Cohort. Circulation, 2021, 143, 289-291.	1.6	30
183	Cardioprotective mechanisms of the kallikrein–kinin system in diabetic cardiopathy. Current Opinion in Nephrology and Hypertension, 2006, 15, 22-29.	2.0	29
184	Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes. Diabetologia, 2008, 51, 2325-2332.	6.3	29
185	Aggravation of left ventricular dysfunction in patients with biopsy-proven cardiac human herpesvirus A and B infection. Journal of Clinical Virology, 2015, 63, 1-5.	3.1	29
186	Transgenic overexpression of adenine nucleotide translocase 1 protects ischemic hearts against oxidative stress. Journal of Molecular Medicine, 2016, 94, 645-653.	3.9	29
187	Investigating a biomarkerâ€driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum Câ€ŧerminal propeptide of procollagen type I (DROPâ€PIP trial). European Journal of Heart Failure, 2018, 20, 460-470.	7.1	29
188	Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator. Frontiers in Physiology, 2020, 11, 345.	2.8	29
189	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. Journal of Cardiac Failure, 2021, 27, 727-743.	1.7	29
190	Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. International Immunopharmacology, 2003, 3, 335-344.	3.8	28
191	Placenta-Derived Adherent Stromal Cells Improve Diabetes Mellitus-Associated Left Ventricular Diastolic Performance. Stem Cells Translational Medicine, 2017, 6, 2135-2145.	3.3	28
192	CX3CR1 knockout aggravates Coxsackievirus B3-induced myocarditis. PLoS ONE, 2017, 12, e0182643.	2.5	28
193	Improvement of defective sarcoplasmic reticulum Ca 2+ transport in diabetic heart of transgenic rats expressing the human kallikreinâ€∎ gene. FASEB Journal, 2004, 18, 1967-1969.	0.5	27
194	Heart Failure with Normal Ejection Fraction. Herz, 2009, 34, 89-96.	1.1	27
195	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e011194.	3.7	27
196	Fibrosis rather than blood pressure determines cardiac BNP expression in mice. Regulatory Peptides, 2003, 116, 95-100.	1.9	26
197	New perspective on the tissue kallikrein–kinin system in myocardial infarction: Role of angiogenesis and cardiac regeneration. International Immunopharmacology, 2008, 8, 148-154.	3.8	26
198	Simultaneous estimation of NT-proBNP on top to mitral flow Doppler echocardiography as an accurate strategy to diagnose diastolic dysfunction in HFNEF. International Journal of Cardiology, 2011, 149, 23-29.	1.7	26

#	Article	IF	CITATIONS
199	Human Endomyocardial Biopsy Specimen-Derived Stromal Cells Modulate Angiotensin II-Induced Cardiac Remodeling. Stem Cells Translational Medicine, 2016, 5, 1707-1718.	3.3	26
200	Cardiac (myo)fibroblasts modulate the migration of monocyte subsets. Scientific Reports, 2018, 8, 5575.	3.3	26
201	Serum alarmin S100A8/S100A9 levels and its potential role as biomarker in myocarditis. ESC Heart Failure, 2020, 7, 1442-1451.	3.1	26
202	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
203	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2021, 117, 2148-2160.	3.8	26
204	Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. Regenerative Medicine, 2006, 1, 235-254.	1.7	25
205	Chronic inhibition of p38MAPK improves cardiac and endothelial function in experimental diabetes mellitus. European Journal of Pharmacology, 2007, 554, 40-45.	3.5	25
206	Upâ€regulation of PPARγ in myocardial infarction. European Journal of Heart Failure, 2008, 10, 30-38.	7.1	25
207	Increased Left Ventricular Stiffness Impairs Exercise Capacity in Patients with Heart Failure Symptoms Despite Normal Left Ventricular Ejection Fraction. Cardiology Research and Practice, 2011, 2011, 1-10.	1.1	25
208	Feasibility and safety of left ventricular endomyocardial biopsy via transradial access: Technique and initial experience. Catheterization and Cardiovascular Interventions, 2015, 86, 761-765.	1.7	25
209	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders, 2022, 7, 24-32.	1.7	25
210	Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype. Frontiers in Cardiovascular Medicine, 2021, 8, 720690.	2.4	25
211	Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball. Current Cardiology Reports, 2017, 19, 70.	2.9	24
212	Impact of aspirin on takotsubo syndrome: a propensity scoreâ€based analysis of the InterTAK Registry. European Journal of Heart Failure, 2020, 22, 330-337.	7.1	24
213	Management perspectives from the 2019 Wuhan international workshop on fulminant myocarditis. International Journal of Cardiology, 2021, 324, 131-138.	1.7	24
214	Substance P and neurokinin A induced desentization to cardiovascular and behavioral effects: evidence for the involvement of different tachykinin receptors. Brain Research, 1993, 625, 75-83.	2.2	23
215	AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. FASEB Journal, 2002, 16, 1237-1241.	0.5	23
216	Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. European Journal of Pharmacology, 2006, 550, 143-148.	3.5	23

#	Article	IF	CITATIONS
217	Endomyocardial biopsy derived adherent proliferating cells—A potential cell source for cardiac tissue engineering. Journal of Cellular Biochemistry, 2010, 109, 564-575.	2.6	23
218	Repetitive levosimendan treatment in the management of advanced heart failure. European Heart Journal Supplements, 2018, 20, 111-120.	0.1	23
219	Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies. Heart Failure Reviews, 2020, 25, 277-294.	3.9	23
220	Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis. ESC Heart Failure, 2022, 9, 925-941.	3.1	23
221	Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor. Biological Chemistry, 2008, 389, 713-718.	2.5	22
222	Lower limit of normality and clinical relevance of left ventricular early diastolic strain rate for the detection of left ventricular diastolic dysfunction. European Heart Journal Cardiovascular Imaging, 2018, 19, 905-915.	1.2	22
223	Apolipoprotein A-I gene transfer exerts immunomodulatory effects and reduces vascular inflammation and fibrosis in ob/ob mice. Journal of Inflammation, 2016, 13, 25.	3.4	21
224	The non-invasive assessment of myocardial work by pressure-strain analysis: clinical applications. Heart Failure Reviews, 2022, 27, 1261-1279.	3.9	21
225	Heart failure with preserved ejection fraction according to the HFAâ€PEFF score in COVID â€19 patients: clinical correlates and echocardiographic findings. European Journal of Heart Failure, 2021, 23, 1891-1902.	7.1	21
226	Protective Function of STAT3 in CVB3-Induced Myocarditis. Cardiology Research and Practice, 2012, 2012, 1-11.	1.1	20
227	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. Cardiovascular Research, 2017, 113, 906-914.	3.8	20
228	Prediction of short―and longâ€ŧerm mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	7.1	20
229	Prediction of survival of patients in cardiogenic shock treated by surgically implanted Impella 5+ short-term left ventricular assist device. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 475-482.	1.1	20
230	Cardiac kinin level in experimental diabetes mellitus: role of kininases. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H418-H423.	3.2	19
231	Renin inhibitors, clinical experience. Journal of Molecular Medicine, 2008, 86, 691-695.	3.9	19
232	Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2018, 5, 53-62.	3.1	19
233	Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy. International Immunopharmacology, 2010, 10, 207-212.	3.8	18
234	Cardiac Cell Therapies: The Next Generation. Cardiovascular Therapeutics, 2011, 29, 2-16.	2.5	18

#	Article	IF	CITATIONS
235	The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure. Clinical Pharmacology and Therapeutics, 2019, 106, 1198-1208.	4.7	18
236	Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. Journal of the American Heart Association, 2021, 10, e014059.	3.7	18
237	Angiotensin deficiency in mice leads to dilated cardiomyopathy. European Journal of Pharmacology, 2004, 493, 161-165.	3.5	17
238	Combination of RNA Interference and Virus Receptor Trap Exerts Additive Antiviral Activity in Coxsackievirus B3-induced Myocarditis in Mice. Journal of Infectious Diseases, 2015, 211, 613-622.	4.0	17
239	Long noncoding <scp>RNA</scp> s: A new player in the prevention and treatment of diabetic cardiomyopathy?. Diabetes/Metabolism Research and Reviews, 2018, 34, e3056.	4.0	17
240	Central cardiovascular and behavioral effects of carboxy- and amino-terminal fragments of substance P in conscious rats. Brain Research, 1995, 690, 15-24.	2.2	16
241	Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol. European Journal of Pharmacology, 2004, 491, 173-179.	3.5	16
242	Kinins in cardiac inflammation and regeneration: Insights from ischemic and diabetic cardiomyopathy. Neuropeptides, 2010, 44, 119-125.	2.2	16
243	Lack in Treatment Options for Virus-Induced Inflammatory Cardiomyopathy. Circulation Research, 2014, 115, 540-541.	4.5	16
244	Treatment of Heart Failure in Realâ€World Clinical Practice: Findings From the <scp>REFLECTâ€HF</scp> Registry in Patients With <scp>NYHA</scp> Class <scp>II</scp> Symptoms and a Reduced Ejection Fraction. Clinical Cardiology, 2015, 38, 200-207.	1.8	16
245	Endomyocardial biopsy and ultrastructural changes in dilated cardiomyopathy: taking a â€~deeper' look into patients' prognosis. European Heart Journal, 2015, 36, 708-710.	2.2	16
246	Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. Cardiovascular Research, 2020, 116, 1756-1766.	3.8	16
247	How to perform an endomyocardial biopsy?. Turk Kardiyoloji Dernegi Arsivi, 2015, 43, 572-5.	0.5	16
248	Upregulation of the cardiac bradykinin B2 receptors after myocardial infarction. Immunopharmacology, 1999, 44, 111-117.	2.0	15
249	Acute Exposure to Doxorubicin Results in Increased Cardiac P-glycoprotein Expression. Journal of Pharmaceutical Sciences, 2011, 100, 3951-3958.	3.3	15
250	Heart Failure 2012. Cardiology Research and Practice, 2012, 2012, 1-3.	1.1	15
251	Immune attributes of cardiac-derived adherent proliferating (CAP) cells in cardiac therapy. Journal of Tissue Engineering and Regenerative Medicine, 2013, 7, 362-370.	2.7	15
252	Postprocedural radial artery occlusion rate using a sheathless guiding catheter for left ventricular endomyocardial biopsy performed by transradial approach. BMC Cardiovascular Disorders, 2016, 16, 253.	1.7	15

#	Article	IF	CITATIONS
253	Efficacy of RADPAD protective drape during coronary angiography. Herz, 2018, 43, 310-314.	1.1	15
254	The role of fibroblast – Cardiomyocyte interaction for atrial dysfunction in HFpEF and hypertensive heart disease. Journal of Molecular and Cellular Cardiology, 2019, 131, 53-65.	1.9	15
255	COVIDâ€19â€convalescence phase unmasks a silent myocardial infarction due to coronary plaque rupture. ESC Heart Failure, 2021, 8, 971-973.	3.1	15
256	High-Density Lipoprotein-Raising Strategies: Update 2010. Current Pharmaceutical Design, 2010, 16, 1517-1530.	1.9	14
257	Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy. Current Pharmaceutical Design, 2011, 17, 3295-3307.	1.9	14
258	Latent ischaemia as a trigger for a <i>circulus vitiosus</i> of inflammation, fibrosis, and stiffness in HFPEF. European Journal of Heart Failure, 2015, 17, 1210-1212.	7.1	14
259	Early Treatment of Coxsackievirus B3–Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005250.	3.9	14
260	Usefulness and clinical relevance of left ventricular global longitudinal systolic strain in patients with heart failure with preserved ejection fraction. Heart Failure Reviews, 2020, 25, 67-73.	3.9	14
261	Further localization of cardiovascular and behavioral actions of substance P in the rat brain. Brain Research, 1994, 668, 100-106.	2.2	13
262	Bradykinin excretion is increased in severely hyperglycemic streptozotocin-diabetic rats. Immunopharmacology, 1996, 33, 344-348.	2.0	13
263	Coronary vasospasm–induced acute diastolic dysfunction in a patient with Raynaud's phenomenon. Clinical Research in Cardiology, 2006, 95, 344-348.	3.3	13
264	High-density lipoproteins reduce palmitate-induced cardiomyocyte apoptosis in an AMPK-dependent manner. Biochemical and Biophysical Research Communications, 2015, 466, 272-277.	2.1	13
265	Cardiac Migration of Endogenous Mesenchymal Stromal Cells in Patients with Inflammatory Cardiomyopathy. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	13
266	Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis. ESC Heart Failure, 2020, 7, 2838-2852.	3.1	13
267	Mechanobiological Principles Influence the Immune Response in Regeneration: Implications for Bone Healing. Frontiers in Bioengineering and Biotechnology, 2021, 9, 614508.	4.1	13
268	Early detection of cardiac alterations by left atrial strain in patients with risk for cardiac abnormalities with preserved left ventricular systolic and diastolic function. International Journal of Cardiovascular Imaging, 2018, 34, 701-711.	1.5	13
269	Clinical correlates and prognostic impact of neurologic disorders in Takotsubo syndrome. Scientific Reports, 2021, 11, 23555.	3.3	13
270	Development of diabetic cardiomyopathy and the kallikrein-kinin system – new insights from B1 and B2 receptor signaling. Biological Chemistry, 2008, 389, 707-711.	2.5	12

Carsten TschĶpe

#	Article	IF	CITATIONS
271	Immunomodulatory Effects of Mesenchymal Stromal Cells Revisited in the Context of Inflammatory Cardiomyopathy. Stem Cells International, 2013, 2013, 1-16.	2.5	12
272	Can speckle-tracking imaging improve the reliability of echocardiographic parameters for outcome evaluation in clinical trials?. European Heart Journal, 2014, 35, 605-607.	2.2	12
273	Potential usefulness and clinical relevance of a novel left atrial filling index to estimate left ventricular filling pressures in patients with preserved left ventricular ejection fraction. European Heart Journal Cardiovascular Imaging, 2020, 21, 260-269.	1.2	12
274	Sex differences in circulating proteins in heart failure with preserved ejection fraction. Biology of Sex Differences, 2020, 11, 47.	4.1	12
275	Speckle-tracking echocardiography combined with imaging mass spectrometry assesses region-dependent alterations. Scientific Reports, 2020, 10, 3629.	3.3	12
276	Angiotensin AT ₂ Receptor Deficiency After Myocardial Infarction: Its Effects on Cardiac Function and Fibrosis Depend on the Stimulus. Cell Biochemistry and Biophysics, 2005, 43, 045-052.	1.8	11
277	Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model. Biological Chemistry, 2008, 389, 719-23.	2.5	11
278	Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2012, 12, 132-147.	1.2	11
279	Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: A randomized double-blinded placebo-controlled study. International Journal of Cardiology, 2012, 161, 137-142.	1.7	11
280	Giant cell myocarditis: still a conundrum. The need for a worldwide registry. European Journal of Heart Failure, 2016, 18, 1459-1461.	7.1	11
281	Accurate assessment of LV function using the first automated 2D-border detection algorithm for small animals - evaluation and application to models of LV dysfunction. Cardiovascular Ultrasound, 2019, 17, 7.	1.6	11
282	QRS fragmentation as a possible electrocardiographic diagnostic marker in patients with acute myocarditis: preliminary histopathological validation. ESC Heart Failure, 2020, 7, 2527-2533.	3.1	11
283	Brief Research Report: Quantitative Analysis of Potential Coronary Microvascular Disease in Suspected Long-COVID Syndrome. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	11
284	A P19 and P19CL6 Cell-Based Complementary Approach to Determine Paracrine Effects in Cardiac Tissue Engineering. Cells Tissues Organs, 2014, 199, 24-36.	2.3	10
285	Human Parvovirus B19 (B19V) Up-regulates CXCR4 Surface Expression of Circulating Angiogenic Cells: Implications for Cardiac Ischemia in B19V Cardiomyopathy. Journal of Infectious Diseases, 2018, 217, 456-465.	4.0	10
286	The atrial appendage as a suitable source to generate cardiacâ€derived adherent proliferating cells for regenerative cellâ€based therapies. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, e1404-e1417.	2.7	10
287	Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function. ESC Heart Failure, 2020, 7, 3531-3535.	3.1	10
288	Propensity scoreâ€based analysis of 30â€day survival in cardiogenic shock patients supported with different microaxial left ventricular assist devices. Journal of Cardiac Surgery, 2021, 36, 4141-4152.	0.7	10

#	Article	IF	CITATIONS
289	Inhibition of Coagulation Factor Xa Improves Myocardial Function During <scp>CVB</scp> 3â€Induced Myocarditis. Cardiovascular Therapeutics, 2014, 32, 113-119.	2.5	9
290	"One Size Does Not Fit All― JACC: Heart Failure, 2016, 4, 460-463.	4.1	9
291	The "TIDE―Algorithm for the Weaning of Patients With Cardiogenic Shock and Temporarily Mechanical Left Ventricular Support With Impella Devices. A Cardiovascular Physiology-Based Approach. Frontiers in Cardiovascular Medicine, 2021, 8, 563484.	2.4	9
292	Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis. ESC Heart Failure, 2021, 8, 2428-2437.	3.1	9
293	Diastolic Heart Failure and LV Dyssynchrony. Current Pharmaceutical Biotechnology, 2012, 13, 2539-2544.	1.6	9
294	The Spontaneous Course of Human Herpesvirus 6 DNA-Associated Myocarditis and the Effect of Immunosuppressive Intervention. Viruses, 2022, 14, 299.	3.3	9
295	Renal expression of two rat kallikrein genes under diabetic conditions. Journal of Hypertension, 1997, 15, 1711-1714.	0.5	8
296	The cardiovascular influence of interleukin-1β on the expression of bradykinin B1 and B2 receptors. International Immunopharmacology, 2008, 8, 222-230.	3.8	8
297	Endomyocardial biopsy in Anderson–Fabry disease: The key in uncertain cases. International Journal of Cardiology, 2015, 190, 284-286.	1.7	8
298	Lost in markers? Time for phenomics and phenomapping in dilated cardiomyopathy. European Journal of Heart Failure, 2017, 19, 499-501.	7.1	8
299	Comorbidity "depression―in heart failure — Potential target of patient education and self-management. BMC Cardiovascular Disorders, 2017, 17, 48.	1.7	8
300	MALDIâ€IMS as a Tool to Determine the Myocardial Response to Syndecanâ€2â€Selected Mesenchymal Stromal Cell Application in an Experimental Model of Diabetic Cardiomyopathy. Proteomics - Clinical Applications, 2021, 15, e2000050.	1.6	8
301	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	3.1	8
302	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. Clinical Research in Cardiology, 2022, 111, 186-196.	3.3	8
303	A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy. Journal of Cardiovascular Translational Research, 2021, 14, 75-87.	2.4	8
304	Low permanent pacemaker rates following Lotus device implantation for transcatheter aortic valve replacement due to modified implantation protocol. Cardiology Journal, 2017, 24, 250-258.	1.2	8
305	Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies. European Heart Journal, 2019, 40, 979-981.	2.2	7
306	Bradykinin and Cardiac Protection. Advances in Experimental Medicine and Biology, 1997, 432, 159-172.	1.6	7

#	Article	IF	CITATIONS
307	Stabilin-1 mediates beneficial monocyte recruitment and tolerogenic macrophage programming during CVB3-induced viral myocarditis. Journal of Molecular and Cellular Cardiology, 2022, 165, 31-39.	1.9	7
308	Diastolic heart failure and LV dyssynchrony. Current Pharmaceutical Biotechnology, 2012, 13, 2539-44.	1.6	7
309	Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic miceThis article is one of a selection of papers published in the special issue (part 1 of 2) on Forefronts in Endothelin Canadian Journal of Physiology and Pharmacology, 2008, 86, 353-357.	1.4	6
310	Acute stimulation of the soluble guanylate cyclase does not impact on left ventricular capacitance in normal and hypertrophied porcine hearts in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H669-H680.	3.2	6
311	Correlation Between Thymus Radiology and Myasthenia Gravis in Clinical Practice. Frontiers in Neurology, 2018, 9, 1173.	2.4	6
312	Proteomic Analysis Reveals Upregulation of ACE2 (Angiotensin-Converting Enzyme 2), the Putative SARS-CoV-2 Receptor in Pressure–but Not Volume-Overloaded Human Hearts. Hypertension, 2020, 76, e41-e43.	2.7	6
313	An optimized imaging protocol for [99mTc]Tc-DPD scintigraphy and SPECT/CT quantification in cardiac transthyretin (ATTR) amyloidosis. Journal of Nuclear Cardiology, 2021, 28, 2483-2496.	2.1	6
314	Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 92-101.	3.0	6
315	Diastolic Heart Failure and LV Dyssynchrony. Current Pharmaceutical Biotechnology, 2012, 13, 2539-2544.	1.6	5
316	The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports. BMC Cardiovascular Disorders, 2018, 18, 155.	1.7	5
317	Myeloid-Derived Suppressor Cells Restrain Natural Killer Cell Activity in Acute Coxsackievirus B3-Induced Myocarditis. Viruses, 2021, 13, 889.	3.3	5
318	Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction: knowing more and understanding less?. European Journal of Heart Failure, 2021, 23, 964-972.	7.1	5
319	Wearable cardioverterâ€defibrillator: friend or foe in suspected myocarditis?. ESC Heart Failure, 2021, 8, 2591-2596.	3.1	5
320	Interventricular Differences of Signaling Pathways-Mediated Regulation of Cardiomyocyte Function in Response to High Oxidative Stress in the Post-Ischemic Failing Rat Heart. Antioxidants, 2021, 10, 964.	5.1	5
321	Patient with heart failure: importance to treat valvular diseases. European Heart Journal Supplements, 2020, 22, P38-P41.	0.1	5
322	First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination. Integrated Blood Pressure Control, 2010, 3, 163.	1.2	4
323	Coronary microvascular dysfunction in heart failure with preserved ejection fraction – adding new pieces to the jigsaw puzzle. European Journal of Heart Failure, 2020, 22, 442-444.	7.1	4
324	Case Report First-in-Man Method Description: Left Ventricular Unloading With iVAC2L During Veno-Arterial Extracorporeal Membrane Oxygenation: From Veno-Arterial Extracorporeal Membrane Oxygenation to ECMELLA to EC-iVAC®. Frontiers in Cardiovascular Medicine, 2020, 7, 563448.	2.4	4

Carsten TschĶpe

#	Article	IF	CITATIONS
325	Impact of Syndecan-2-Selected Mesenchymal Stromal Cells on the Early Onset of Diabetic Cardiomyopathy in Diabetic db/db Mice. Frontiers in Cardiovascular Medicine, 2021, 8, 632728.	2.4	4
326	Pro-Angiogenic Effect of Endomyocardial Biopsy-Derived Cells for Cardiac Regeneration. Current Tissue Engineering, 2013, 2, 154-159.	0.2	4
327	Diuretic dosing in heart failure: more data are needed. ESC Heart Failure, 2018, 5, 649-650.	3.1	3
328	Myocardial Fibrosis Due to ExorbitantÂExercise or Just UndetectedÂPost-Inflammatory Stages?. JACC: Cardiovascular Imaging, 2019, 12, 381-382.	5.3	3
329	8 Kallikrein-kinin system in the heart. , 2011, , .		3
330	Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction-A Specific HFpEF Phenotype. Frontiers in Cardiovascular Medicine, 2021, 8, 720690.	2.4	3
331	CMR findings after COVID-19 and after COVID-19-vaccination—same but different?. International Journal of Cardiovascular Imaging, 2022, 38, 2057-2071.	0.6	3
332	Graded lower body negative pressure induces intraventricular negative pressures and incremental diastolic suction: a pressure-volume study in a porcine model. Journal of Applied Physiology, 2022, 133, 20-26.	2.5	3
333	Reversible transition from a hypertrophic to a dilated cardiomyopathy. ESC Heart Failure, 2016, 3, 138-142.	3.1	2
334	Adenosine stress perfusion cardiac magnetic resonance imaging in patients undergoing intracoronary bone marrow cell transfer after ST-elevation myocardial infarction: the BOOST-2 perfusion substudy. Clinical Research in Cardiology, 2020, 109, 539-548.	3.3	2
335	Being in Two Minds—The Challenge of Heart Failure with Preserved Ejection Fraction Diagnosis with a Single Biomarker. Clinical Chemistry, 2021, 67, 46-49.	3.2	1
336	A Patient with Quadricuspid Aortic Valve and Ischemic Stroke. Journal of Heart Valve Disease, 2016, 25, 456-458.	0.5	1
337	Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions?. BMC Cardiovascular Disorders, 2017, 17, 253.	1.7	0
338	CMR Assessment of Myocyte Disarray in HCM. Journal of the American College of Cardiology, 2019, 74, 1847-1848.	2.8	0
339	Case Report: Early Transplant Rejection of a Methanol-Intoxicated Donor Heart in a Young Female Patient. A Diagnostic Approach With CMR, Cardiac Biopsy, and Genetic Risk Assessment. Frontiers in Immunology, 2020, 11, 575635.	4.8	0
340	Reply to â€~Heart failure with preserved ejection fraction and <scp>COVID</scp> â€19: which comes first, the chicken or the egg?'. European Journal of Heart Failure, 2021, 23, 2092-2093.	7.1	0
341	Aging and Diastolic Dysfunction: The Interplay of Inflammation and Extracellular Matrix Regulation. , 2014, , 183-198.		0

0

#	Article	IF	CITATIONS
343	Antiviral Therapies: A Critical Reappraisal. , 2020, , 297-316.		0

344 Myokarditis: Meist mit Defektheilung. , 0, , .